WO1995031462A1 - Hymenialdisine et derive de celle-ci, procede pour produire un intermediaire servant a synthetiser ce compose, et cet intermediaire - Google Patents
Hymenialdisine et derive de celle-ci, procede pour produire un intermediaire servant a synthetiser ce compose, et cet intermediaire Download PDFInfo
- Publication number
- WO1995031462A1 WO1995031462A1 PCT/JP1995/000941 JP9500941W WO9531462A1 WO 1995031462 A1 WO1995031462 A1 WO 1995031462A1 JP 9500941 W JP9500941 W JP 9500941W WO 9531462 A1 WO9531462 A1 WO 9531462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- tert
- formula
- compound
- compound represented
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 28
- 230000008569 process Effects 0.000 title abstract description 4
- QPCBNXNDVYOBIP-WHFBIAKZSA-N hymenialdisine Chemical compound NC1=NC(=O)C([C@@H]2[C@@H]3C=C(Br)N=C3C(=O)NCC2)=N1 QPCBNXNDVYOBIP-WHFBIAKZSA-N 0.000 title abstract description 3
- ATBAETXFFCOZOY-UHFFFAOYSA-N hymenialdisine Natural products N1C(N)=NC(=O)C1=C1C(C=C(Br)N2)=C2C(=O)NCC1 ATBAETXFFCOZOY-UHFFFAOYSA-N 0.000 title abstract description 3
- 230000002194 synthesizing effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 139
- 125000005843 halogen group Chemical group 0.000 claims abstract description 19
- -1 trimethylsilylethoxymethyl group Chemical group 0.000 claims description 89
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 6
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 5
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 5
- 229960001867 guaiacol Drugs 0.000 claims description 5
- LHGVFZTZFXWLCP-UHFFFAOYSA-N pyrocatechol monomethyl ether Natural products COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims description 5
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 3
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000002140 halogenating effect Effects 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims 3
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 150000001502 aryl halides Chemical class 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 102000003923 Protein Kinase C Human genes 0.000 abstract description 4
- 108090000315 Protein Kinase C Proteins 0.000 abstract description 4
- 229910052736 halogen Inorganic materials 0.000 abstract description 4
- 229910052739 hydrogen Chemical group 0.000 abstract description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 2
- 230000004913 activation Effects 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 239000001257 hydrogen Chemical group 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 23
- 239000000203 mixture Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 238000001816 cooling Methods 0.000 description 17
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000003756 stirring Methods 0.000 description 13
- 239000002904 solvent Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 239000012442 inert solvent Substances 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 5
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- DXZDEAJXVCLRLE-UHFFFAOYSA-N azepin-2-one Chemical compound O=C1C=CC=CC=N1 DXZDEAJXVCLRLE-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 229960001701 chloroform Drugs 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- AAPGLCCSVSGLFH-UHFFFAOYSA-N 1,5,6,7-tetrahydropyrrolo[2,3-c]azepine-4,8-dione Chemical compound O=C1CCNC(=O)C2=C1C=CN2 AAPGLCCSVSGLFH-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 238000010531 catalytic reduction reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- DSPXASHHKFVPCL-UHFFFAOYSA-N 1-isocyanocyclohexene Chemical compound [C-]#[N+]C1=CCCCC1 DSPXASHHKFVPCL-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000243308 Hymeniacidon Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- LADPCMZCENPFGV-UHFFFAOYSA-N chloromethoxymethylbenzene Chemical compound ClCOCC1=CC=CC=C1 LADPCMZCENPFGV-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- SIGOIUCRXKUEIG-UHFFFAOYSA-N methyl 2-dimethoxyphosphorylacetate Chemical compound COC(=O)CP(=O)(OC)OC SIGOIUCRXKUEIG-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Inorganic materials [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000006257 total synthesis reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- PDVFSPNIEOYOQL-UHFFFAOYSA-N (4-methylphenyl)sulfonyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OS(=O)(=O)C1=CC=C(C)C=C1 PDVFSPNIEOYOQL-UHFFFAOYSA-N 0.000 description 1
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- DNZXMWKFPMIKRG-UHFFFAOYSA-N 1-(chloromethoxymethyl)-4-methoxybenzene Chemical compound COC1=CC=C(COCCl)C=C1 DNZXMWKFPMIKRG-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- SENLRGPGOSFQIG-UHFFFAOYSA-N 1-methylpyridin-1-ium-2-ol;iodide Chemical compound [I-].C[N+]1=CC=CC=C1O SENLRGPGOSFQIG-UHFFFAOYSA-N 0.000 description 1
- SFGNNBCWQOIVAZ-UHFFFAOYSA-N 1h-pyrrole-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN1 SFGNNBCWQOIVAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- MKHGVMIXRPGHOO-UHFFFAOYSA-N 2-(benzenesulfonyl)-3-phenyloxaziridine Chemical compound C=1C=CC=CC=1S(=O)(=O)N1OC1C1=CC=CC=C1 MKHGVMIXRPGHOO-UHFFFAOYSA-N 0.000 description 1
- CIACLSGBPZWWNK-UHFFFAOYSA-N 2-(chloromethoxy)-2-methylpropane Chemical compound CC(C)(C)OCCl CIACLSGBPZWWNK-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MWWNNNAOGWPTQY-UHFFFAOYSA-N 3-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(S(Cl)(=O)=O)=C1 MWWNNNAOGWPTQY-UHFFFAOYSA-N 0.000 description 1
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000677022 Axinella verrucosa Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- GGVJJDVUAGRHEE-UHFFFAOYSA-N CC(O[SiH2]CCCCCC)(C)Cl Chemical compound CC(O[SiH2]CCCCCC)(C)Cl GGVJJDVUAGRHEE-UHFFFAOYSA-N 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- XQPLTMZAEGUQSB-UHFFFAOYSA-N ClOC(C)(C)C.ClN1C(N(C(N(C1=O)Cl)=O)Cl)=O Chemical compound ClOC(C)(C)C.ClN1C(N(C(N(C1=O)Cl)=O)Cl)=O XQPLTMZAEGUQSB-UHFFFAOYSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OUKRFPQCDBUDOG-UHFFFAOYSA-N N1CCOCC1.[I] Chemical compound N1CCOCC1.[I] OUKRFPQCDBUDOG-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241000287463 Phalacrocorax Species 0.000 description 1
- 241000243142 Porifera Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 229940077239 chlorous acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- UVJHQYIOXKWHFD-UHFFFAOYSA-N cyclohexa-1,4-diene Chemical compound C1C=CCC=C1 UVJHQYIOXKWHFD-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- YGMUWVFVRVJUEC-UHFFFAOYSA-N ethane-1,2-diamine;tetrabutylazanium Chemical compound NCCN.CCCC[N+](CCCC)(CCCC)CCCC YGMUWVFVRVJUEC-UHFFFAOYSA-N 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- QGJJOACVGVBTHP-UHFFFAOYSA-N ethoxy-(2-ethoxy-2-oxoethyl)phosphinic acid Chemical compound CCOC(=O)CP(O)(=O)OCC QGJJOACVGVBTHP-UHFFFAOYSA-N 0.000 description 1
- HUNISAHOCCASGM-UHFFFAOYSA-N ethyl 2-dimethoxyphosphorylacetate Chemical compound CCOC(=O)CP(=O)(OC)OC HUNISAHOCCASGM-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- IXROPUMCCWLBHJ-UHFFFAOYSA-N fluoroform;sulfuryl dichloride Chemical compound FC(F)F.ClS(Cl)(=O)=O IXROPUMCCWLBHJ-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- AKPUJVVHYUHGKY-UHFFFAOYSA-N hydron;propan-2-ol;chloride Chemical class Cl.CC(C)O AKPUJVVHYUHGKY-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N methyl monoether Natural products COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- KPBSJEBFALFJTO-UHFFFAOYSA-N propane-1-sulfonyl chloride Chemical compound CCCS(Cl)(=O)=O KPBSJEBFALFJTO-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical group OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- DOYOPBSXEIZLRE-UHFFFAOYSA-N pyrrole-3-carboxylic acid Natural products OC(=O)C=1C=CNC=1 DOYOPBSXEIZLRE-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 229950009390 symclosene Drugs 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IYLFKXATVSYTQV-UHFFFAOYSA-N tert-butyl-(chloromethoxy)-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCl IYLFKXATVSYTQV-UHFFFAOYSA-N 0.000 description 1
- FMHIJPWZPYTIEF-UHFFFAOYSA-N tert-butyl-(chloromethoxy)-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](OCCl)(C(C)(C)C)C1=CC=CC=C1 FMHIJPWZPYTIEF-UHFFFAOYSA-N 0.000 description 1
- DGCFCIXSJPYNLX-UHFFFAOYSA-N trichloromethylsulfonyl trichloromethanesulfonate Chemical compound ClC(Cl)(Cl)S(=O)(=O)OS(=O)(=O)C(Cl)(Cl)Cl DGCFCIXSJPYNLX-UHFFFAOYSA-N 0.000 description 1
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Definitions
- the present invention provides a compound of formula (I):
- X 1 represents a halogen atom or a hydrogen atom
- the present invention relates to a method for producing hymenialdisine represented by the following formula, a derivative thereof and a salt thereof.
- the present invention further relates to an intermediate for producing the compound (I) and a method for producing the intermediate.
- Acanthel la aurantiaca (Cimino, G .: Tetrahedron Lett., 23, 767 (1982)), Hymeniacidon aldis (Kitagawa, I. et al .: Chem. Pharm. Bull., 31_, 2321 (1983)) and an unidentified Kololevu sponge (Schmitz, F. et al .: J. Nat. Prod., 48, 47 (1985)), and debromohymenial dicine is Phakelli. flabe_llata (Sharma, G. et al .: J. Chem. So, Chem. Commun., 435 (1980)) and Hymeniacidon aldis (itagawa, I. et al .: Chem. Pharm. Bull., 31, 2321 (1983); Endo, M. et al .: Pure & Appl. Chem., 58, 387 (1986)).
- the compound in which X 1 is a bromine atom is hymeniardin
- the compound in which X 1 is a hydrogen atom is debromohymenidicin, which have an interesting biological activity.
- Hymenialdicine and debromohymenialdicin are known to have antitumor activity (Pettit, G. et al .: Can. J.
- hymenialdicine and debromohymenidialin have been known to be protein oxidases, especially protein kinase C (Nishizuka, Y .: Nature, 334, 661 (1988), which plays an important role in cell signaling).
- protein kinase C idem, JAMA, 262, 1826 (1989)
- pathological conditions thought to involve the activation of protein kinase C such as , Cerebral ischemic disorder, cerebral vasospasm, ischemic heart disease, hypertension, arteriosclerosis, inflammation, asthma, renal disorder, rheumatoid arthritis, enhancement of immune function, etc. I have.
- an object of the present invention is to provide an efficient production method for mass-producing Hymenialdicine and its derivatives economically.
- Another object of the present invention is to provide a synthetic intermediate useful for producing these compounds and a method for producing the same.
- X 1 represents a halogen atom or a hydrogen atom
- Step 3 Compound (V) is obtained from compound (IV) (step 4), and compound (Via) is obtained from compound (V) (step 5). Compound (Va) is obtained from compound UVa).
- step 6 Compound (VII) is obtained from compound (VI) (step 7).
- step 8 The target compound which is the compound (I) is obtained from the obtained compound (VII) (step 8).
- R ⁇ represents a hydrogen atom or a carboxyl-protecting group
- R 2 represents a trimethylsilylethoxymethyl group, a benzyloxymethyl group, a p-methoxybenzyloxymethyl group, a methoxymethyl group, A methoxymethyloxy group, a tert-butoxymethyl group, a p-anisyloxymethyl group, a guaiacol methyl group, a tert-butyldimethylsiloxymethyl group, a dimethyltexylsiloxymethyl group or a tert-butyldiphenylsilyloxymethyl group;
- R 3 is the trim Represents a tylsilylethoxymethyl group, a benzyloxymethyl group, a P-methoxybenzyloxymethyl group, a tert-butyldimethylsiloxymethyl group, a dimethyltexylsilyloxymethyl group or a tert-butyl
- the compound represented by (X) can be produced.
- the group which can be easily exchanged with the amino group in the group W of the compound (VIII) include a halogen atom and a carboxylic acid residue.
- the protective group for the carboxyl group includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl and t-butyl.
- Compound (X) is synthesized using “Compendium for Organic Synthesis”.
- organic or inorganic base optionally in the presence of an organic or inorganic base
- cyanide getylphosphate DEPC
- DPPA Azide diphenylate
- DCC dicyclohexylcarbodiimide
- 1-ethyl 3- (3-dimethylaminopropyl) carbodiimide hydrochloride 2-hydroxy 1-methylpyridinium iodide
- Etc. can be used.
- compound (X) is converted to (XI) by a halogenation reaction.
- compound (X) is converted to methylene chloride, 1,2-dichloroethane, chloroform, acetonitril, tetrahydrofuran, dioxane, ethylene glycol dimethyl ether, dimethylforma 0.3 to 1.2 equivalents of N-chlorosuccinimide, trichloroisocyanuric acid, tert-chlorous acid in an inert solvent such as amide at 50 to 100, preferably 110 to 60 ° C.
- the obtained compound (XI) is subjected to a cyclization reaction, if necessary, by removing the protecting group by an action of an acid or a base or by a suitable means such as catalytic reduction.
- the compound (XI) is reacted with an organic acid such as methanesulfonic acid or an inorganic acid such as sulfuric acid or polyphosphoric acid or a mixture of these with phosphorus pentoxide at room temperature to 170 ° C. It is preferably carried out at a temperature of 80 to 130 ° C. In this case, a solvent that does not participate in the reaction may be added as necessary.
- the obtained compound (XII) is hydrogenated in an inert solvent such as dimethylformamide, dimethylsulfoxide, tetrahydrofuran, ethylene glycol dimethyl ether, dioxane, benzene, toluene and xylene.
- an inert solvent such as dimethylformamide, dimethylsulfoxide, tetrahydrofuran, ethylene glycol dimethyl ether, dioxane, benzene, toluene and xylene.
- a base such as sodium, hydrogen hydride or potassium tert-butoxide
- the obtained compound (XIII) was dissolved in an inert solvent such as dimethylformamide, dimethylsulfoxide, tetrahydrofuran, ethylene glycol dimethyl ether, dioxane, benzene, toluene, xylene, etc.
- an inert solvent such as dimethylformamide, dimethylsulfoxide, tetrahydrofuran, ethylene glycol dimethyl ether, dioxane, benzene, toluene, xylene, etc.
- a base such as sodium hydride, potassium hydride, or potassium tert-butoxide
- 0.8 to 1.5 equivalents of trimethylsilyl chloride is preferably used.
- the compound (XIV) obtained can be separated and purified by a commonly used purification method, for example, column chromatography, to give the compound of formula
- the compound represented by the formula (Ila) can also be obtained by fractionating a compound in which X 2 is a halogen atom and X 3 is a hydrogen atom from the mixture (XIII) and using it in the next step.
- the 1-position protection and the 7-position protection are carried out in the same manner as in the step of producing the compound ( ⁇ ) from the compound (XII). Can be performed in one process.
- the compound obtained in each of the above reactions can be used as it is in the next step, but if necessary, it can be used after purification by a commonly used purification method, for example, recrystallization / column chromatography. Good.
- Aldicine (XV) as a raw material is a known compound described in Prager, R. et al .: Aust. J. Chem., 43, ⁇ 355-365 (1990). This step can be performed in the same manner as in the method for obtaining compound (XIV) from compound (II) in step 1.
- the obtained compound (lib) can be used in the next step as it is, but if necessary, may be used after purification by a generally used purification method, for example, recrystallization or column chromatography.
- the compound represented by formula (IV) can be obtained by reacting the compound represented by formula (II) obtained in step 1 or 2 with dialkyl phosphonoacetate (III).
- R ′ represents an optionally substituted alkyl group having 1 to 4 carbon atoms, and any one of the dotted lines is present. To indicate a single bond.
- This step is performed in an inert solvent such as tetrahydrofuran, dioxane, ethylene glycol dimethyl ether, benzene, toluene, xylene, dimethylformamide, etc. in a sodium hydride, potassium hydride, sodium 0-120 ° C, preferably room temperature-70, in the presence of bases such as lithium methoxide, sodium ethoxide and potassium tert.
- an inert solvent such as tetrahydrofuran, dioxane, ethylene glycol dimethyl ether, benzene, toluene, xylene, dimethylformamide, etc.
- a sodium hydride, potassium hydride, sodium 0-120 ° C, preferably room temperature-70 in the presence of bases such as lithium methoxide, sodium ethoxide and potassium tert.
- the compound (IV) obtained by the above method can be used as it is as a raw material for producing the compound (V), but if necessary, a purification method generally used, for example, column chromatography may be used. Alternatively, the compound (IVa) used in step 6 may be separated and then purified before use.
- R 1 , R 2 , R 3, and X 1 are as defined above, and a dotted line indicates a single bond when any one is present.
- This step is performed in an inert solvent such as tetrahydrofuran, getyl ether, diethyl glycol dimethyl ether, and toluene.
- an inert solvent such as tetrahydrofuran, getyl ether, diethyl glycol dimethyl ether, and toluene.
- (Trimethylsilyl) amidocarium, bis (trimethylsilyl) amidonatomium, lithium bis (trimethylsilyl) amido, lithium diisopropiramide At a temperature of 100 to 20 ° C, preferably -78 to 0 ° C, in the presence of a strong base such as chloride, 1 to 1.5 equivalents of 2-benzenesulfonyl-13-phenyloxaziryl based on compound (IV).
- Gin Davis, F. et al .: J. Org.
- the compound (V) obtained by the above method can be used as it is as a raw material for producing the compound (Via), but if necessary, a purification method generally used, for example, a column chromatography may be used. It may be used after purification.
- the compound represented by the formula (Via) can be obtained by sulfonylating the hydroxyl group of the compound (V) obtained in the step 4.
- R 4 is an alkylsulfonyloxy group or an arylsulfonyloxy group
- preferable alkyl group is carbon Alkyl group of number 1-4
- halogen And substituted methyl groups preferable halogens include a fluorine atom and a chlorine atom
- preferable aryl groups include a phenyl group, a P-trile group, and a 4-methoxyphenyl group. Group, 4-chlorophenyl group, and ditrophenyl group.
- This process includes methylene chloride, 1,2-dichloroethane, chloroform, carbon tetrachloride, acetonitrile, getyl ether, tetrahydrofuran, dioxane, benzene, toluene, In an inert solvent such as xylene or ethyl acetate, triethylamine, diisopropylethylamine, pyridine, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, or hydrogencarbonate In the presence of a base such as platinum, at ⁇ 20 to 100, preferably 1 to 10 to 60 ° C., 1 to 10 equivalents of methanesulfonyl chloride and methanesulfonic anhydride in an amount of 1 to 10 equivalents to compound (V) Tansulfonyl chloride, 1-propanesulfonyl chloride, 1-bromosulfonyl chloride, trifluoromethan sulphonyl chloride, trifluo
- the compound (Via) obtained by the above method can be used as it is as a raw material for producing the compound (VII), but if necessary, it can be purified by a commonly used purification method, for example, column chromatography. You may use it later.
- R 1 , R 2 , R 3 and X 1 are as defined above, and R 5 represents a halogen atom.
- compound (IVa) was converted to methylene chloride, dichloromethane, chloroform, acetonitril, tetrahydrofuran, dioxane, ethylene glycol dimethyl ether, dimethylforma
- inert solvents such as amides, at 50 to 120 ° C, preferably at 20 to 80 ° C, 0.3 to 2 equivalents of N-cycloconodiimide, trichloroisocyanuric acid Tert-butyl hypochlorite, iodine trichloride, N-bromosuccinic acid imide, bromine, dioxane / bromine complex, 2,4,6,6-tetrabutyl 2,5-cyclohexadiene, N— Halogens such as iodo-condonic acid imid, iodine, iodine-zium-potassium iodide, iodine-z-periodic acid, iodine
- the compound (VIb) obtained by the above method can be used as it is as a raw material for producing the compound (VII), but if necessary, a purification method generally used, for example, column chromatography may be used. It may be used after purification. Step 7 :
- the compound represented by the formula (VII) is obtained by reacting guanidine with the compound represented by the formula (VI) obtained in step 5 or 6.
- R 1 , R 2 , R 3 and X 1 are as defined above, and R 6 represents an alkylsulfonyloxy group, an arylsulfonyloxy group or a halogen atom.
- This step is carried out by adding compound (VI) to an inert solvent such as benzene, toluene, xylene, tetrahydrofuran, dioxane, ethylene glycol dimethyl ether, dimethylformamide, or dimethylsulfoxide.
- an inert solvent such as benzene, toluene, xylene, tetrahydrofuran, dioxane, ethylene glycol dimethyl ether, dimethylformamide, or dimethylsulfoxide.
- the reaction may be carried out by reacting 1 to 10 equivalents of guanidine at 200 ° C., preferably at room temperature to 120, for 2 to 24 hours.
- the compound (VII) obtained by the above method can be used as a raw material for producing the compound (I) as it is, but if necessary, a purification method generally used, for example, recrystallization or force chromatography can be used. May be used after purification.
- This step is carried out at a temperature of 150 to 150 ° C., preferably at a temperature of 120 to 120 ° C., and 1 to 10 equivalents of compound (VII).
- this step can be performed using a general deprotect
- Compound (I) obtained by the above method can be purified by a commonly used purification method, for example, recrystallization or column chromatography.
- Compound (I) can be obtained as a pharmacologically acceptable salt according to a conventional method, and examples thereof include inorganic acids such as hydrochloric acid, nitric acid, sulfuric acid, hydrobromic acid, and phosphoric acid. , Maleic acid, fumaric acid, tartaric acid, citric acid, lactic acid, oxalic acid, acetic acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, adipic acid, palmitic acid, tannic acid, etc.
- an acid addition salt of the compound represented by the formula (I) can be produced.
- Example 1 2—Promote 4—Ethoxycarbonyl—Liden—1,7 Di (trimethylsilyl ethoxymethyl) — 4,5,6,7 —tetrahydropyro [2,3-c] azepine 18-one (9) and 2—promo 4—e Synthesis of Toquincarbonylmethyl-1,6-di (trimethylsilylethoxymethyl) -16,7-dihydropyro [2,3-c] _azepin-18-one (10)
- Example 2 4—ethoxycarbonylylidene 7—di (trimethylsilylethoxymethyl) 1-4,5,6,7—tetrahydropyrro [2,3—c] azepine 18 -One (11) and 4-ethoxycarbonylmethyl-1,7-di (trimethylsilylethoxymethyl) -1-6,7-dihydropyrro [2,3—c] azepine-18-one (12) Synthesis
- Example 6 4-ethoxycarbonyl (methansulfonyloxy) methyl-1,1,7-di (trimethylsilylethoxymethyl) -16,7-dihydropyrro [2,3-c] azepine Synthesis of 8-one (16) Compound (14) 840 mg synthesized in Example 4 in the same manner as in Example 5 From 0.69 ml of triethylamine and 0.15 ml of methansulfonyl chloride, 940 mg of the title compound (16) ( Yield 97%).
- Example 8 4- (2-amino-4,1-oxo-2-imidazoline-1-5-1ylidene) -1,2-promo 1,7-di (trimethylsilylethoxymethyl) -1,4, 5,6,7—Synthesis of Tetrahydropyrro [2,3——c] azepin-18-one (18)
- Table 1 shows the physicochemical data of the compound obtained in the above reference example
- Table 2 shows the physicochemical data of the compound obtained in the example.
- ADVANTAGE OF THE INVENTION According to this invention, it can be economically and efficiently mass-produced by high-molecular-weight synthesis and its derivative by total chemical synthesis. Further, an intermediate useful for producing the compound can be provided.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95918732A EP0711773B1 (en) | 1994-05-18 | 1995-05-17 | Hymenialdisine and derivative thereof, process for producing intermediate for synthesizing the same, and said intermediate |
US08/586,638 US5621099A (en) | 1994-05-18 | 1995-05-17 | Synthetic method of hymenialdisine and its derivatives and their synthetic intermediates, and those synthetic intermediates |
KR1019960700258A KR960703916A (ko) | 1994-05-18 | 1995-05-17 | 하이메니알디신 및 그의 유도체, 그들의 합성 중간체 제조법 및 그의 합성 중간체(hymenialdisine and derivative thereof, process for producing intermediate for synthesizing the same, and said intermediate) |
DE69522642T DE69522642T2 (de) | 1994-05-18 | 1995-05-17 | Hymenialdisin und seine derivate, verfahren zur herstellung von zwischenprodukten zu ihrer synthese und besagte zwischenprodukte |
AU24541/95A AU701436B2 (en) | 1994-05-18 | 1995-05-17 | Synthetic method of hymenialdisine and its derivatives and their synthetic intermediates, and those synthetic intermediates |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/104030 | 1994-05-18 | ||
JP10403094A JP3714685B2 (ja) | 1994-05-18 | 1994-05-18 | ハイメニアルディシン及びその誘導体並びにそれらの合成中間体の製造法並びにその合成中間体 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995031462A1 true WO1995031462A1 (fr) | 1995-11-23 |
Family
ID=14369852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/000941 WO1995031462A1 (fr) | 1994-05-18 | 1995-05-17 | Hymenialdisine et derive de celle-ci, procede pour produire un intermediaire servant a synthetiser ce compose, et cet intermediaire |
Country Status (9)
Country | Link |
---|---|
US (1) | US5621099A (ja) |
EP (1) | EP0711773B1 (ja) |
JP (1) | JP3714685B2 (ja) |
KR (1) | KR960703916A (ja) |
AU (1) | AU701436B2 (ja) |
CA (1) | CA2167515A1 (ja) |
DE (1) | DE69522642T2 (ja) |
ES (1) | ES2160164T3 (ja) |
WO (1) | WO1995031462A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115245170A (zh) * | 2021-04-28 | 2022-10-28 | 南开大学 | Aldisin及其生物碱衍生物在防治植物病毒、杀虫、杀菌方面的应用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE255582T1 (de) * | 1993-04-08 | 2003-12-15 | Univ Columbia | Verfahren zur synthese von 4-und/oder 5-(di) substituierten 2-aminoimidazolen aus 2- aminoimidazolen und aldehyden |
JP3563076B2 (ja) * | 1995-12-01 | 2004-09-08 | 第一サントリーファーマ株式会社 | ピロロアゼピン誘導体 |
CA2216559A1 (en) * | 1997-09-25 | 1999-03-25 | Michel Roberge | G2 checkpoint inhibitors and assay |
US6197954B1 (en) | 1998-01-30 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Intermediates for the synthesis of debromohymenialdisine and processes thereof |
US6211361B1 (en) * | 1999-07-20 | 2001-04-03 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon, State Univeristy | Method for making debromohymenialdisine and analogs thereof |
EP1106180B1 (en) * | 1999-12-08 | 2003-11-12 | Centre National de la Recherche Scientifique (CNRS) | Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
IL150763A0 (en) * | 2000-01-24 | 2003-02-12 | Genzyme Corp | Jak/stat inhibitors and pharmaceutical compositions containing the same |
RU2294931C2 (ru) | 2000-05-11 | 2007-03-10 | Консехо Супериор Инвестигасионес Сьентификас | Гетероциклические ингибиторы гликоген-синтазы киназы gsk-3 |
RU2005119173A (ru) * | 2002-12-20 | 2006-02-27 | Фармация Корпорейшн (Us) | Ациклические пиразольные соединения |
US7423031B2 (en) * | 2003-05-01 | 2008-09-09 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2004103958A2 (en) * | 2003-05-19 | 2004-12-02 | Michigan State University | Preparation of hymenialdisine derivatives and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62161786A (ja) * | 1986-01-08 | 1987-07-17 | Mitsubishi Chem Ind Ltd | ピロ−ル化合物 |
JPH02500738A (ja) * | 1986-05-29 | 1990-03-15 | ハーバー ブランチ オーシャノグラフィック インスチチューション インコーポレイテッド | 抗腫瘍組成物およびその使用法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3198117B2 (ja) * | 1990-02-07 | 2001-08-13 | サントリー株式会社 | ピロロアゼピン誘導体 |
DE69323185T2 (de) * | 1992-02-24 | 1999-07-08 | Smithkline Beecham Corp | Proteinkinase c-inhibitor |
-
1994
- 1994-05-18 JP JP10403094A patent/JP3714685B2/ja not_active Expired - Fee Related
-
1995
- 1995-05-17 ES ES95918732T patent/ES2160164T3/es not_active Expired - Lifetime
- 1995-05-17 CA CA002167515A patent/CA2167515A1/en not_active Abandoned
- 1995-05-17 AU AU24541/95A patent/AU701436B2/en not_active Ceased
- 1995-05-17 US US08/586,638 patent/US5621099A/en not_active Expired - Fee Related
- 1995-05-17 DE DE69522642T patent/DE69522642T2/de not_active Expired - Fee Related
- 1995-05-17 WO PCT/JP1995/000941 patent/WO1995031462A1/ja active IP Right Grant
- 1995-05-17 KR KR1019960700258A patent/KR960703916A/ko not_active Application Discontinuation
- 1995-05-17 EP EP95918732A patent/EP0711773B1/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62161786A (ja) * | 1986-01-08 | 1987-07-17 | Mitsubishi Chem Ind Ltd | ピロ−ル化合物 |
JPH02500738A (ja) * | 1986-05-29 | 1990-03-15 | ハーバー ブランチ オーシャノグラフィック インスチチューション インコーポレイテッド | 抗腫瘍組成物およびその使用法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0711773A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115245170A (zh) * | 2021-04-28 | 2022-10-28 | 南开大学 | Aldisin及其生物碱衍生物在防治植物病毒、杀虫、杀菌方面的应用 |
Also Published As
Publication number | Publication date |
---|---|
JPH07309874A (ja) | 1995-11-28 |
DE69522642T2 (de) | 2002-04-18 |
EP0711773A4 (ja) | 1996-06-19 |
EP0711773B1 (en) | 2001-09-12 |
DE69522642D1 (de) | 2001-10-18 |
AU2454195A (en) | 1995-12-05 |
CA2167515A1 (en) | 1995-11-23 |
US5621099A (en) | 1997-04-15 |
AU701436B2 (en) | 1999-01-28 |
JP3714685B2 (ja) | 2005-11-09 |
KR960703916A (ko) | 1996-08-31 |
EP0711773A1 (en) | 1996-05-15 |
ES2160164T3 (es) | 2001-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5268912B2 (ja) | 環状11−βヒドロキシステロイドデヒドロゲナーゼI型阻害剤 | |
JP6746613B2 (ja) | ウレア誘導体、またはその薬理学的に許容される塩 | |
TWI294878B (en) | Dioxan-2-ylalkylcarbamate derivatives, their preparation and their use in therapeutics | |
FR2640266A2 (fr) | Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique | |
WO1995031462A1 (fr) | Hymenialdisine et derive de celle-ci, procede pour produire un intermediaire servant a synthetiser ce compose, et cet intermediaire | |
WO1995005374A1 (fr) | Derive de cyclopentene heteroaromatique fusionne ayant une activite antagoniste de l'endotheline | |
CN109575013A (zh) | 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病 | |
KR102477924B1 (ko) | 인돌 카르복스아미드 화합물을 제조하는 방법 | |
WO1985004172A1 (en) | Polyazaheterocyclic derivatives, process for their preparation, and pharmaceutical composition | |
US5948907A (en) | Synthesis of bisindolylmaleimides | |
CN112142746B (zh) | 苯二氮卓类化合物及其制备方法和在医药上的作用 | |
JP2007230963A (ja) | 2,4−ジ置換ピリジンの製造法 | |
JP4181219B2 (ja) | 環縮合したジヒドロピラン類、その製造方法およびその使用 | |
US20050245750A1 (en) | Process for preparing 1,3-benzodioxole-2-spirocycloalkane derivative | |
JP4823221B2 (ja) | 新規な不飽和四環式テトラヒドロフラン誘導体 | |
CN114901639B (zh) | Hbv抑制剂及其用途 | |
WO1995026964A1 (fr) | Derive dc-89 | |
JP2001526257A (ja) | ナフタレン誘導体 | |
TW200418838A (en) | Compounds for the treatment of premature ejaculation | |
JP2000507969A (ja) | キラル添加剤を用いる非対称コンジュゲート付加反応によるエンドセリン中間体 | |
JPH05246994A (ja) | キノリルメトキシフエニル−アセトアミド類 | |
JPH04187686A (ja) | インドロカルバゾール誘導体 | |
WO1996032394A1 (fr) | DERIVES DE PYRAZOLO[1,5-a]PYRIMIDINE | |
JP2003505390A (ja) | 抗炎症薬用のピロリジンのオキソ及びヒドロキシ誘導体、並びにその使用方法 | |
JP2004244425A (ja) | ハイメニアルディシン及びその誘導体の合成中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA KR LT SI US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2167515 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08586638 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995918732 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1995918732 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995918732 Country of ref document: EP |